362 related articles for article (PubMed ID: 15634647)
21. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B.
Tadini-Buoninsegni F; Bartolommei G; Moncelli MR; Inesi G; Galliani A; Sinisi M; Losacco M; Natile G; Arnesano F
Angew Chem Int Ed Engl; 2014 Jan; 53(5):1297-301. PubMed ID: 24375922
[TBL] [Abstract][Full Text] [Related]
22. Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.
Lai YH; Kuo C; Kuo MT; Chen HHW
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772714
[TBL] [Abstract][Full Text] [Related]
23. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K
Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422
[TBL] [Abstract][Full Text] [Related]
24. The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin.
Larson CA; Adams PL; Blair BG; Safaei R; Howell SB
Mol Pharmacol; 2010 Sep; 78(3):333-9. PubMed ID: 20519567
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT
Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438
[TBL] [Abstract][Full Text] [Related]
26. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
[TBL] [Abstract][Full Text] [Related]
27. The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin.
Larson CA; Adams PL; Jandial DD; Blair BG; Safaei R; Howell SB
Biochem Pharmacol; 2010 Aug; 80(4):448-54. PubMed ID: 20451502
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
29. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1.
Chen HH; Song IS; Hossain A; Choi MK; Yamane Y; Liang ZD; Lu J; Wu LY; Siddik ZH; Klomp LW; Savaraj N; Kuo MT
Mol Pharmacol; 2008 Sep; 74(3):697-704. PubMed ID: 18523133
[TBL] [Abstract][Full Text] [Related]
30. Interaction between platinum complexes and the C-terminal motif of human copper transporter 1.
Wang E; Xi Z; Li Y; Li L; Zhao L; Ma G; Liu Y
Inorg Chem; 2013 May; 52(10):6153-9. PubMed ID: 23642142
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin.
Liang ZD; Stockton D; Savaraj N; Tien Kuo M
Mol Pharmacol; 2009 Oct; 76(4):843-53. PubMed ID: 19570948
[TBL] [Abstract][Full Text] [Related]
32. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
[TBL] [Abstract][Full Text] [Related]
33. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007
[TBL] [Abstract][Full Text] [Related]
34. Role of copper transporters in the uptake and efflux of platinum containing drugs.
Safaei R
Cancer Lett; 2006 Mar; 234(1):34-9. PubMed ID: 16297532
[TBL] [Abstract][Full Text] [Related]
35. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
36. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
Safaei R; Howell SB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):13-23. PubMed ID: 15607932
[TBL] [Abstract][Full Text] [Related]
37. Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells.
Buß I; Hamacher A; Sarin N; Kassack MU; Kalayda GV
Metallomics; 2018 Mar; 10(3):414-425. PubMed ID: 29417972
[TBL] [Abstract][Full Text] [Related]
38. Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
Oncotarget; 2016 Aug; 7(31):49310-49321. PubMed ID: 27384479
[TBL] [Abstract][Full Text] [Related]
39. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.
Chen HH; Chen WC; Liang ZD; Tsai WB; Long Y; Aiba I; Fu S; Broaddus R; Liu J; Feun LG; Savaraj N; Kuo MT
Expert Opin Ther Targets; 2015; 19(10):1307-17. PubMed ID: 26004625
[TBL] [Abstract][Full Text] [Related]
40. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
